Kevin Anderson
Family Medicine · Chickasha, OKNPI 1154655157
Payments from drug & device makers
Across 76 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$254
- GSK$165
- Abbott$124
- Bayer$117
- AbbVie$85
- Johnson & Johnson$85
- plus $354 from 13 others
What the payments were for
- Food & beverage$1,182100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $254 |
| GSK | 10 | $165 |
| Abbott | 8 | $124 |
| Bayer | 7 | $117 |
| AbbVie | 4 | $85 |
| Johnson & Johnson | 6 | $85 |
| Sunovion Pharmaceuticals Inc. | 9 | $73 |
| Pfizer | 3 | $43 |
| Tersera Therapeutics LLC | 2 | $38 |
| Astellas Pharma US Inc | 2 | $34 |
| Amgen | 1 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Dexcom, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Merck | 1 | $12 |
| Novartis | 1 | $12 |
How this compares
$1,182 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 109 | $105,960 |
| EliquisApixaban | 122 | $97,353 |
| JardianceEmpagliflozin | 73 | $94,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $59,541 |
| TrulicityDulaglutide | 55 | $57,972 |
| JanuviaSitagliptin Phosphate | 43 | $54,885 |
| OzempicSemaglutide | 44 | $38,282 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $30,510 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $26,522 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 52 | $24,731 |
| FarxigaDapagliflozin Propanediol | 22 | $24,610 |
| EntrestoSacubitril/Valsartan | 21 | $17,950 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $15,395 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,507 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $12,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $13 | $163,932164 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $31 | $106,34096 claims |
| PfizerEliquis | $43 | $97,353122 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $165 | $88,245154 claims |
| MerckJanuvia | $12 | $54,88543 claims |
| Novo NordiskOzempic | $254 | $38,28244 claims |
| NovartisEntresto | $12 | $17,95021 claims |
| AbbVieLinzess | $85 | $12,20816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Chickasha
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.